Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 weeks (Part 1) and with or without ribavirin for 16, 28 or 40 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase Ib/II)

Trial Profile

Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with ribavirin for 4 weeks (Part 1) and with or without ribavirin for 16, 28 or 40 weeks (Part 2) in patients with chronic HCV genotype 1 infection (randomized, open label, Phase Ib/II)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SOUND-C1; SOUND-C2; SOUND-C3
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Apr 2014 Pharmacogenomic analysis presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 02 Apr 2014 As per the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Oct 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top